Similarly, no notable variations were observed between the TBI and non-TBI groups in terms of chronic kidney disease (19.0% vs. 18.5%, respectively; p = 0.859); diabetes mellitus (13.1% vs. 17.9%, respectively; p = 0.141); or current use of oral hypoglycemic agents or insulin (9.5% vs. 11.8%, respectively; p = 0.415), antihypertensive drugs (23.2% vs. 29.0%, respectively; p = 0.281), lipid-lowering drugs (13.7% vs. 12.5%, respectively; p = 0.682), or hormone drugs (2.4% vs. 2.1%, respectively; p = 0.824). This evidence concerns the gene INS and diabetes mellitus.